The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer.
 
Ritu Salani
Consulting or Advisory Role - Eisai; GlaxoSmithKline/Tesaro; Immunogen; Karyopharm Therapeutics; Merck; Regeneron; Seagen
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Mansoor Mirza
Stock and Other Ownership Interests - Karyopharm, Sera
Honoraria - AstraZeneca, GSK, MSD, Eisai
Consulting or Advisory Role - AstraZeneca, GSK, MSD, Eisai
Research Funding - AstraZeneca, GSK, Ultimovacs
 
Zhongqiu Lin
No Relationships to Disclose
 
Shin Nishio
No Relationships to Disclose
 
Ana Oaknin
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OncoXerna Therapeutics; PharmaMar; Regeneron; Roche; Seagen / Pfizer; Shattuck Labs; Sutro Biopharma; TORL Therapuetics; Zentalis; Zymeworks
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Immunogen; MSD; Roche
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Jean Emmanuel Kurtz
Employment - MSD (I)
Honoraria - GSK, AstraZeneca, Eisai, MSD, Abbvie
Consulting or Advisory Role - GSK, AstraZeneca, Eisai, MSD, Abbvie
 
Giorgio Valabrega
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD
Consulting or Advisory Role - Eisai; GlaxoSmithKline
Travel, Accommodations, Expenses - MSD
 
Valeria Cáceres
No Relationships to Disclose
 
Philipp Harter
Honoraria - Abbvie; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Eisai; Exscientia; GlaxoSmithKline; Karyopharm Therapeutics; Lilly; Mersana; MSD Oncology; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech SE; Clovis Oncology; Corcept Therapeutics; Eisai; Exscientia; GlaxoSmithKline; Immunogen; Merck; Mersana; Miltenyi Biomedicine; MSD Oncology; Novartis; Roche; Tesaro; Zymeworks
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Immunogen (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Lucy Gilbert
Honoraria - GlaxoSmithKline; Merck; Repare Therapeutics
Consulting or Advisory Role - Corcept Therapeutics; Eisai; GlaxoSmithKline; Immunogen; Kora Healthcare; Merck
Research Funding - Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Esperas Pharma (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Immunogen (Inst); IMV (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Repare Therapeutics (Inst); Roche (Inst); Seagen (Inst); Shattuck Labs (Inst); Sutro BioPharma Inc (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Corcept Therapeutics; Eisai; EndomEra; GlaxoSmithKline; GOG Foundation; Merck; Zentalis
 
Azmat Sadozye
No Relationships to Disclose
 
Lilian Arruda De Rêgo Barros
Speakers' Bureau - Janssen, Novartis, AstraZeneca, Daiichi-Sankyo, Pfizer, Roche, Zodiac, Lilly, Gilead
 
Toon Van Gorp
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst); Tubulis GmbH (Inst); Zentalis (Inst)
Speakers' Bureau - Abbvie (Inst); AstraZeneca (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Ingrid Boere
Consulting or Advisory Role - AstraZeneca (Inst)
 
Christian Marth
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD
Consulting or Advisory Role - Abbvie; BeiGene; BioNTech; Eisai; Genmab; GlaxoSmithKline; MSD; Seagen
 
Linda Duska
Consulting or Advisory Role - Ellipses Pharma (Inst); Inovio Pharmaceuticals; Merck (Inst); Regeneron
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Syndax (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Editor, British Journal of Ob/Gyn; UpToDate
 
Bradley Monk
Honoraria - Abbvie; AstraZeneca; BioNTech SE; Corcept Therapeutics; DSI; Eisai; Genmab; Genmab/Seagen; GlaxoSmithKline; GOG Foundation; Immunogen; Incyte; Karyopharm Therapeutics; Lilly; Merck; Mersana; Mural; Myriad Genetics; Natera; Novartis; Novocure; Onco4; Panavance Therapeutics; Pharma&; ProfoundBio; Regeneron; Roche/Genentech; Sutro Biopharma; Tubulis GmbH; Verastem; Zentalis; Zymeworks
Consulting or Advisory Role - Abbvie; Alkermes; AstraZeneca; BioNTech SE; Corcept Therapeutics; DSI; Eisai; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Incyte; Karyopharm Therapeutics; Lilly; Merck; Mersana; Myriad Pharmaceuticals; Natera; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pharma&; ProfoundBio; Regeneron; Roche/Genentech; Sutro Biopharma; Tubulis GmbH; Verastem; Zentalis; Zymeworks
Speakers' Bureau - AstraZeneca; Eisai; Immunogen/Abbvie; Lilly; Merck; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Xin Tong Li
Employment - Merck
 
Cumhur Tekin
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Kristina Lindemann
Honoraria - GSK, Nycode, MSD, AstraZeneca, Eisai
Consulting or Advisory Role - GSK, Nycode, MSD, AstraZeneca, Eisai
Research Funding - GlaxoSmithKline
Other Relationship - Karyopharm (DSMC)
 
TroFuse-020/GOG-3101/ENGOT-cx20 Study Group
No Relationships to Disclose